Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

In the first head-to-head comparison of leading incretin-based therapies, Eli Lilly’s dual GIP/GLP-1 receptor agonist ...

Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...

Nearly 32% of Zepbound users lost at least a quarter of their body weight, compared with about 16% of Wegovy users. In both ...

Ozempic side effects are a hot topic but don’t panic – our experts are here to help. Here’s what to expect and how to ...

While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...

The head-to-head examination of these weight loss drugs provides doctors with 'robust' data on their effectiveness.

The side effects of the two drugs combined include dizziness, abnormal sensations, altered taste, insomnia, constipation and ...

The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...